Long-term survival following multidisciplinary treatment of metastatic XXXX : a case report.

@entity1 @entity16231 @entity5 @entity3446 @entity2239 @entity1358 @entity3 @entity811 @entity4149
INTRODUCTION: We report the case of a 62-year-old @entity1 diagnosed with @entity1358 . CASE PRESENTATION: A 62-year-old Asian @entity1 presented with macroscopic @entity811 . A histological and immunohistochemical study of a @entity5 biopsy specimen led to a suspected diagnosis of @entity1358 . She underwent surgical @entity5 resection that included her left kidney. A histological and immunohistochemical study of the resected @entity5 confirmed the diagnosis of @entity1358 . The pathological stage was pT3bpN2, and multiple lung @entity3 were detected (pT3bpN2cM1; stage IV). Our @entity1 was classified as "poor risk" according to the Memorial Sloan Kettering Cancer Center risk criteria. Interferon-a was administered as adjuvant therapy, and her lung @entity3 remained stable. However, a computed tomography scan and bone scintigraphy 2 years later revealed multiple bone @entity3 . External beam radiotherapy was performed for the bone @entity3 . Despite continuing interferon-a during radiotherapy, multiple skull and liver @entity3 appeared. Oral administration of the @entity4149 kinase inhibitor @entity16231 was initiated as a second-line therapy, and our @entity1 achieved a stable state for 11 months. As the liver @entity3 progressed and meningeal dissemination newly appeared, oral administration of the @entity1 target of @entity3446 inhibitor @entity2239 was initiated as a third-line therapy. Our @entity1 remains alive 71 months after diagnosis and has maintained a comparatively good quality of life. CONCLUSION: A literature review revealed that metastatic @entity1358 has very poor prognosis, with a survival of <1 year despite systemic therapy. Our @entity1 in this present case achieved long-term survival, a rare incidence worthy of report.
